NCT00303927View on ClinicalTrials.gov

Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene

PHASE2CompletedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

September 30, 2007

Conditions
Pancreatic Cancer
Interventions
DRUG

capecitabine

Trial Locations (2)

28041

Hospital Universitario 12 de Octubre, Madrid

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT00303927 - Capecitabine as Second-Line Therapy in Treating Patients With Stage IV Pancreatic Cancer Who Have the Thymidylate Synthase Gene | Biotech Hunter | Biotech Hunter